Research

Perinatal transmission of human papillomavirus DNA

Renato L Rombaldi*1,3,4, Eduardo P Serafini2,3, Jovana Mandelli1, Edineia Zimmermann1 and Kamille P Losquiavo1

Address: 1Diagnosis – Molecular Laboratory, University of Caxias do Sul, Caxias do Sul, Rio Grande do Sul, Brazil, 2Pathology Medical Laboratory, Department of Health and Biomedical Science, University of Caxias do Sul, Caxias do Sul, Rio Grande do Sul, Brazil, 3Biotechnology Institute, University of Caxias do Sul, Caxias do Sul, Rio Grande do Sul, Brazil and 4Outpatient Clinic of Genital Pathology, Department of Clinical Medicine, University of Caxias do Sul, Caxias do Sul, Rio Grande do Sul, Brazil

Email: Renato L Rombaldi* - rl.rombaldi@gmail.com; Eduardo P Serafini - epserafini@diagnosers.com.br; Jovana Mandelli - jomandelli@terra.com.br; Edineia Zimmermann - edineia@zimmermann-rs.com.br; Kamille P Losquiavo - kamillepl@hotmail.com

* Corresponding author

Abstract

The purpose was to study the perinatal transmission of human papillomavirus DNA (HPV-DNA) in 63 mother-newborn pairs, besides looking at the epidemiological factors involved in the viral DNA transmission. The following sampling methods were used: (1) in the pregnant woman, when was recruited, in cervix and clinical lesions of the vagina, vulva and perineal region; (2) in the newborn, (a) buccal, axillary and inguinal regions; (b) nasopharyngeal aspirate, and (c) cord blood; (3) in the children, buccal was repeated in the 4th week and 6th and 12th month of life. HPV-DNA was identified using two methodologies: multiplex PCR (PGMY09 and MY11 primers) and nested-PCR (genotypes 6/11, 16, 18, 31, 33, 42, 52 and 58). Perinatal transmission was considered when concordance was found in type-specific HPV between mother/newborn or mother/child. HPV-DNA genital was detected in 49 pregnant women submitted to delivery. Eleven newborns (22.4%, n = 11/49) were HPV-DNA positive. In 8 cases (16.3%, n = 8/49) there was type specific HPV concordance between mother/newborn samples. At the end of the first month of life three children (6.1%, n = 3/49) became HPV-DNA positive, while two remained positive from birth. In 3 cases (100%, n = 3/3) there was type specific HPV concordance between mother/newborn samples. In the 6th month, a child (2%, n = 1/49) had become HPV-DNA positive between the 1st and 6th month of life, and there was type specific HPV concordance of mother/newborn samples. All the HPV-DNA positive children (22.4%, n = 11/49) at birth and at the end first month of life (6.1%, n = 3/49) became HPV-DNA negative at the age of 6 months. The HPV-DNA positive child (2%, n = 1/49) from 1st to the 6th month of life became HPV-DNA negative between the 6th and 12th month of life and one child had anogenital warts. In the twelfth month all (100%, n = 49/49) the children studied were HPV-DNA negative. A positive and significant correlation was observed between perinatal transmission of HPV-DNA and the immunodepression of maternal variables (HIV, p = 0.007). Finally, the study suggests that perinatal transmission of HPV-DNA occurred in 24.5% (n = 12/49) of the cases studied.

Published: 21 June 2009

Virology Journal 2009, 6:83 doi:10.1186/1743-422X-6-83

Received: 3 May 2009 Accepted: 21 June 2009

This article is available from: http://www.virologyj.com/content/6/1/83

© 2009 Rombaldi et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
**Introduction**

Sexual transmission of human papillomaviruses (HPV) is widely recognized as a cause of anogenital warts and cervical cancer[1,2]. Today, the plurality of HPV is well-established; more than 120 HPV types have been identified. Papillomaviruses are also suspected of playing a role in a subset of oropharyngeal cancers, in squamous cell skin cancers, and possibly also in esophageal cancers, though the evidence is as yet less convincing than that for cervical cancer[3].

HPV is a sexually transmitted disease common in adolescents and adults[4]. It is becoming increasingly clear that HPV-DNA can be acquired by non-sexual routes, and that one of these would be mother-child transmission during the perinatal period [5-8]. This vertical transmission of HPV-DNA presumably may occur when the fetus passes through the infected birth canal [9-12] or by ascending infection, especially after premature rupture of the amniotic membranes [5-7]. Several authors referred to the presence of HPV in the amniotic liquid[13], in fetal membranes[12], in nasopharyngeal aspirates of concepts born by cesarean section[9,11], in cord blood[14] suggesting that HPV-DNA contamination occurred before birth (intrauterine) by transplacental route[14]. The implications of these observations have not yet been clearly established. The non-concordance of type specific HPV between mother and newborn appears to suggest the existence of other transmission routes such as by phomites (contaminated instruments), contact between the child and people (interfamily, friends). In children, the vertical transmission of HPV-DNA was related to juvenile recurrent respiratory papillomatosis[15] and to genital warts[16].

Therefore a prospective study was proposed in pregnant women with molecular diagnosis of genital HPV-DNA, as well as their newborns, in order to seek a better understanding of the risks of perinatal transmission of DNA virus, and also to study a few maternal variables that might be correlated with DNA virus transmission.

**Materials and methods**

*Population studied*

Between April 2005 and December 2008, a cross-sectional, prospective study was performed on pregnant women with a prior history of HPV infection, or who had abnormal Papanicolaou smear or genital warts, due to the high probability that they could have HPV infection. The women were referred from the Obstetrical Service of the University of Caxias do Sul and by the Basic Health Units of the Single Health System of Caxias do Sul. This study was performed with the approval of the Ethics Committee in Research at the University of Caxias do Sul, and of the Editorial and Scientific Board of the General Hospital of Caxias do Sul, and did not present a conflict of interest. The Letter of Free and Informed Consent and the epidemiological evaluation tool were obtained from all the women by individual interviews during the obstetrical examinations. At the end of the study 63 pairs of mothers/newborns were included in the research.

**Epidemiological evaluation**

The epidemiological study was performed taking the following variables into account: age, race, level of education, smoking, marital status, marital stability, history of immunodeficiency (HIV – acquired immunodeficiency syndrome), type of HPV lesion (genital warts, LGSIL – low-grade squamous intraepithelial lesions, HGSIL – high-grade squamous intraepithelial lesions), site of HPV lesion (cervical, vaginal, vulvar and perineal), numbers of types of HPV-DNA in maternal genital (single, double and multiple), gestational age at the time HPV infection was diagnosed (weeks), time of labor (minutes), time of amniotic membrane rupture (minutes), type of delivery (cesarean section, vaginal and vaginal with forceps) and HPV lesion at delivery (genital warts, LGSIL – low-grade squamous intraepithelial lesions, HGSIL – high-grade squamous intraepithelial lesions).

**Sampling methods**

*Maternal*

The maternal genital samples were obtained during pregnancy, at the first visit, when the pregnant woman was recruited. The sample was obtained using a special brush for cytopathological sampling of the cervix, which was used for genital brushing in the following order: cervix and possible clinical and subclinical lesions of the vagina, vulva and perineal region. The brush was placed in a TE solution (Tris HCl, pH 7.5 – 10 mM; EDTA, 1 mM), and the material collected was kept frozen at -20°C, until the desoxyribonucleic acid (DNA) was extracted.

*Newborns*

In newborns, in the first minutes of life, buccal, body, nasopharyngeal aspirates and arterial blood were obtained from the umbilical cord samples.

*Buccal and body*

The swabs were collected in the first minutes of life, using the special brush for cytopathological sampling of the cervix, with which brushing was performed in the following order: buccal cavities, axillary and inguinal regions of the newborn. The brush was placed in a TE solution (Tris HCl, pH 7.5 – 10 mM; EDTA, 1 mM) and kept frozen at -20°C, until DNA was extracted.

Collection with a brush from the buccal of the newborn was repeated in the 4th week and 6th and 12th month of life.
**Nasopharyngeal aspirations**

The distal extremity of the tracheal aspiration catheter (n=6 or 8, Sondas Descartáveis Mercosul® Linha Sondas Descartáveis Mercosul®, Empresa CPL Medical’s Produtos Médicos LTDA), used to aspirate the upper airways (nasopharyngeal) of the newborn immediately after birth, was removed. The distal extremity of the catheter (about 4 cm long) was cut and placed in TE solution (Tris HCl, pH 7.5 – 10 mM; EDTA, 1 mM), keeping it frozen at -20°C, until DNA was extracted.

**Arterial cord blood**

The sample was collected directly from one of the arteries of the cord using a 3 ml disposable syringe (27/5 needle) to obtain about 1 ml of fetal blood. The collection was performed after clamping the cord and complete delivery of the placenta and fetal membranes. The fetal blood was placed in a KMA type tube with EDTA and frozen at -20°C, until DNA was extracted.

**DNA extraction**

DNA was extracted in the blood and tissue samples using the Wizard Genomic DNA Purification Kit (Promega), according to the manufacturer’s specifications. In the brush samples, DNA was extracted using 600 μl of NaOH 50 mM, stirred in a vortex for 5–10 seconds and later incubated at 95°C for 5 minutes. The solution was then neutralized with 60 μl of Tris HCl pH 8.0 and kept in a freezer at -20°C, until it was submitted to the next stages.

After the DNA extraction methodology, the products were submitted to two different PCR methods for HPV-DNA identification and typing: PCR multiplex and type specific nested multiplex PCR.

**Amplification of the β-globin and HPV**

The DNA samples obtained from the extraction methodology were amplified in multiplex PCR, and this was composed by the PCO4 oligonucleotides (CAA CTT CAT CCA CGT TCA CC) and GH20 (GAA GAG CCA AGG ACA GGT AC), which amplified the segment of 268 base pairs (bp) of the human β-globin gene, ensuring the qualification and quantification of DNA for HPV analysis, and by the PGM09 and PGMY11 oligonucleotides, which amplify a segment of 450 pb of a preserved region of gene L1 of *Human Papillomavirus*[17]. The thermocycler, model PTC100 (MJResearch, Watertown, Mass) was used for amplification; the parameters for denaturation, annealing and lengthening of the ribbons were the following: 95°C for 5 minutes, followed by 40 51°C cycles for 30 seconds, 55°C for 1 minute, 72°C for 1 minute and, finally, 72°C for 5 minutes. Negative and positive controls were included with all amplifications, and the negative control was constituted by all elements except genomic DNA; and the positive control was constituted by HPV-DNA type 16 previously typing (Diagnosis Molecular Laboratory of University of Caxias do Sul). Four μg of the molecular DNA of the DNA φ X 174RF HaeIII molecular weight marker were used. The presence or absence of HPV-DNA fragments and β-globin amplified from the oligonucleotides was analyzed in 1.5% agarose gel, in buffer TBE 0.5× with 0.3% ethidium bromide (0.1 mg/μL solution), under ultraviolet light.

**Viral typing**

The HPV positive samples were submitted to a new type of PCR-specific for viral type identification. For this purpose the RFLP (Restriction Fragment Length Polymorphism) technique was used, according to the methodology described by Bernard et al. (1994)[18]. The amplified product was digested by the BamHI, Ddel, HaeIII, HinfI, PstI, Rsal and SauAIIII enzymes and analyzed by vertical electrophoresis in 4% polyacrylamide gel (20.3% acrylamide, 0.7% bisacrylamide, 0.07% ammonium persulphate, TBE 1x TEMED 0.7 μL/mL – Gibco-BRL). The pGEM (PROMEGA) was used as a molecular weight marker. Later the samples in polyacrylamide gel were stained with silver nitrate and the fragments obtained compared to the prototypes described by Bernard et al. (1994)[18].

**Amplification by nested-PCR in region E6/E7 of the HPV**

The nested multiplex PCR (NMPCR) assay combines degenerate E6/E7 consensus primers and type-specific primers for the detection and typing of HPV genotypes 6/11, 16, 18, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 56, 58, 59, 66 and 68. As to sensitivity and performance with clinical samples, the novel NMPCR assay is a potentially useful tool for HPV-DNA detection in epidemiologic and clinical follow-up studies, especially when accurate HPV typing and the detection of multiple HPV infections are required.

The samples were amplified in the first PCR reaction using the degenerated primers GP-E6-3F (GGG WGW KAC TGA AAT CGG T), GP-E6-5B (CTG AGC CTA GAG ACA GGT AC), and the PGMY09 and PGMY11 oligonucleotides, which amplify a segment of 450 pb of a preserved region of gene L1 of *Human Papillomavirus*[17]. The thermocycler, model PTC100 (MJResearch, Watertown, Mass) was used for amplification; the parameters for denaturation, annealing and lengthening of the ribbons were the following: 95°C for 5 minutes, followed by 40 51°C cycles for 30 seconds, 55°C for 1 minute, 72°C for 1 minute and, finally, 72°C for 5 minutes. Negative and positive controls were included with all amplifications, and the negative control was constituted by all elements except genomic DNA; and the positive control was constituted by HPV-DNA type 16 previously typing (Diagnosis Molecular Laboratory of University of Caxias do Sul). Four μg of the molecular DNA of the DNA φ X 174RF HaeIII molecular weight marker were used. The presence or absence of HPV-DNA fragments and β-globin amplified from the oligonucleotides was analyzed in 1.5% agarose gel, in buffer TBE 0.5× with 0.3% ethidium bromide (0.1 mg/μL solution), under ultraviolet light.

**Perinatal transmission of HPV-DNA**

In the study, perinatal transmission of HPV-DNA was considered when HPV type-specific agreement was observed between the samples mother/newborn or mother/child.
Statistical analysis

Statistical analyses were performed with the SPSS computer software package (version 12.0 for Windows). Frequency tables were analyzed by using the chi-square test, with Pearson and likelihood ratio tests for the significance of differences between the categorical variables. The 95% confidence interval (95% CI) was calculated where appropriate. Differences in the means of continuous variables between the groups were analyzed by using nonparametric tests. In all analyses, probability values of < 0.05 were regarded as significant.

Results

The genital HPV-DNA was detected in 49 women of the 63 who underwent delivery (mean age 23.9 ± 8 years; 14–41 years). The distribution of the viral types identified in the maternal genital samples are shown in table 2. Among the HPV-DNA positive (HPV-DNA+) cases, 54.9%, 1.2%, 40.2% and 3.7% were considered high risk, possible high risk, low risk and unclassified DNA, respectively[21]. The HPV-DNA detected most frequently were types 6/11 (20.7%), 42 (15.9%), 16 (15.9%), 18 (11%), 58 (6.1%) and 31, 35 and 52 (3.7% each). The numbers of types of HPV-DNA identified in maternal genital were single, double and multiple in 38.8%, 30.6% and 30.6% of the cases, respectively.

When analyzing the samples obtained from buccal and body scrapings, nasopharyngeal aspirate and arterial cord blood obtained during the first minutes of life, it was observed that 11 newborns (NB) (22.4%, n = 11/49) were HPV-DNA+ in samples obtained by scraping the buccal and body, 5 (10.2%, n = 5/49) from the nasopharyngeal aspirate and 3 (6.1%, n = 3/49) in arterial cord blood. Concordance of type specific HPV was seen between the mother/NB in 16.3% (n = 8/49) of the cases. There was type specific HPV concordance

Table 1: Sequences of type-specific nested PCR primers used in this study.

| HPV genotype | Primer sequences | Amplicon (pb)* |
|--------------|------------------|----------------|
| 6/11         | TGC AAG AAT GCA CTG ACC AC TGC ATG TTG TGC AGC AGC TGC CAT ATA TTC ATG CAA TGT AGG TGT A | 334 |
| 16           | CAC AGT TAT GCA CAG AGC TGC GAA ATT GCA TGA ACT AAG CTC G CAC ATA TAC CTT TGT TGG TCA A | 457 |
| 18           | CAC TCC ACT GCA AGA CAT AGA GTT GTG AAA TCG TCG TTT TCC A GAA ATT GCA TGA ACT AAG CTC G | 332 |
| 31           | GTC ATT GCA AGA CAT AGA GTC ATG AAG CTC G CAC ATA TAC CTT TGT TGG TCA A | 263 |
| 33           | ACT ATA CAC AAC ATT GAA CTA GTT TTT ACA CTT CAC AGT AGA | 398 |
| 42           | CCC AAA GTC GTG GTC CCA GTT A GAT CTT TCG TAG TGT CCG AGT G | 277 |
| 52           | TAA GGC TGC AYG TGT TGC AG CTA CTT AGT ATT TCA CTT AAT GGT | 229 |
| 58           | GTA AAG TGT GTC ATG AGA GTT GTT ACA GGT TAC ACT TGG GTT GTC ACG AGT CAC AGT GCA | 274 |

* Base pairs.

The HPV-DNA was detected in 49 women of the 63 who underwent delivery (mean age 23.9 ± 8 years; 14–41 years). The distribution of the viral types identified in the maternal genital samples are shown in table 2. Among the HPV-DNA positive (HPV-DNA+) cases, 54.9%, 1.2%, 40.2% and 3.7% were considered high risk, possible high risk, low risk and unclassified DNA, respectively[21]. The HPV-DNA detected most frequently were types 6/11 (20.7%), 42 (15.9%), 16 (15.9%), 18 (11%), 58 (6.1%) and 31, 35 and 52 (3.7% each). The numbers of types of HPV-DNA identified in maternal genital were single, double and multiple in 38.8%, 30.6% and 30.6% of the cases, respectively.

When analyzing the samples obtained from buccal and body scrapings, nasopharyngeal aspirate and arterial cord blood obtained during the first minutes of life, it was observed that 11 newborns (NB) (22.4%, n = 11/49) were HPV-DNA+ in samples obtained by scraping the buccal and body, 5 (10.2%, n = 5/49) from the nasopharyngeal aspirate and 3 (6.1%, n = 3/49) in arterial cord blood. Concordance of type specific HPV was seen between the mother/NB in 16.3% (n = 8/49) of the cases. There was type specific HPV concordance

Table 2: HPV types in maternal genital sample.

| Type n = 18 | Carcinogenic risk | Frequency n = 82 | % |
|-------------|-------------------|------------------|---|
| 6/11        | LR                | 17               | 20.7 |
| 42          | LR                | 13               | 15.9 |
| 16          | HR                | 13               | 15.9 |
| 18          | HR                | 9                | 11  |
| 58          | HR                | 5                | 6.1  |
| 31          | HR                | 3                | 3.7  |
| 35          | HR                | 3                | 3.7  |
| 52          | HR                | 3                | 3.7  |
| 51          | HR                | 2                | 2.4  |
| 54          | LR                | 2                | 2.4  |
| 59          | HR                | 2                | 2.4  |
| 26          | PRHR              | 1                | 1.2  |
| 33          | HR                | 1                | 1.2  |
| 34          | HR                | 1                | 1.2  |
| 45          | HR                | 1                | 1.2  |
| 68          | HR                | 1                | 1.2  |
| 70          | LR                | 1                | 1.2  |
| 73          | HR                | 1                | 1.2  |
| NC*         | -                 | 3                | 3.7  |

The HPV types were identified by both multiplex PCR and nested multiplex PCR methods.*NC = HPV-DNA positive but could not be classified by type. LR – Low-risk HPV genotypes (HPV type 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 and CP6108); HR – High-risk HPV genotypes (HPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82); PRHR – Probable high-risk HPV genotypes (HPV type 26, 53 and 66)[21].

Page 4 of 12 (page number not for citation purposes)
Table 3: Clinical and laboratory history of genital HPV infection during pregnancy and delivery and distribution of HPV types in maternal, newborns and children in 1<sup>st</sup> and 6<sup>th</sup> and 12<sup>th</sup> month of life samples.

| Maternal epidemiology | HPV type in samples |
|-----------------------|---------------------|
|                       | Pregnancy | Delivery | Maternal | Newborn | Children |
|                       |           |          |          |         |          |
|                       | Buccal    |                                      |

| Case | HPV lesion type | HPV lesion site | Type | HPV lesion | Genital | Nasopharyngeal aspirates | Buccal and body | Cord blood | 1<sup>st</sup> month of life | 6<sup>th</sup> month of life | 12<sup>th</sup> month of life |
|------|-----------------|-----------------|------|------------|---------|-------------------------|-----------------|------------|-----------------------------|-----------------------------|-----------------------------|
| 1    | Warts           | VV              | V    | No         | 6/11    |                         |                 |            |                             |                             |                             |
| 2    | HGSIL           | C               | C    | No         | 16+6/11 | 6/11                    |                |            |                             |                             |                             |
| 3    | HGSIL           | C               | C    | Yes        | 16+31   |                         |                 |            |                             |                             |                             |
| 4    | Warts           | VV              | V    | No         | 16+42+54| 42                      |                 |            |                             |                             |                             |
| 5    | LGSIL           | C               | C    | Yes        | 18      |                         |                 |            |                             |                             |                             |
| 6    | Warts           | VV              | C    | No         | 6/11+16+31|                       |                 |            |                             |                             |                             |
| 7    | Warts           | C+VV+VG         | V    | No         | 6/11+42 | 6/11                    | 6/11            |            |                             |                             |                             |
| 8    | HGSIL           | C               | C    | Yes        | 52      |                         |                 |            |                             |                             |                             |
| 9    | LGSIL           | C               | V    | Yes        | 42+51+NC* |                       |                 |            |                             |                             |                             |
| 10   | Warts           | VV+VG           | V    | No         | 6/11    |                         |                 |            |                             |                             |                             |
| 11   | LGSIL           | C               | V    | No         | 18      |                         | 18              |            |                             |                             |                             |
| 12   | Warts           | VV              | V+F  | No         | NC*     |                         |                 |            |                             |                             |                             |
| 13   | LGSIL           | C               | C    | Yes        | 6/11+42 |                         |                 |            |                             |                             |                             |
| 14   | LGSIL           | C               | C    | Yes        | 16+42+58| 59                      |                 |            |                             |                             |                             |
| 15   | Warts           | C+VV+VG         | V    | Yes        | 6/11+42 |                         |                 |            |                             |                             |                             |
| 16   | Warts           | VV+VG           | C    | No         | 6/11    |                         |                 |            |                             |                             |                             |
| 17   | HGSIL           | C               | C    | Yes        | 18+51   |                         |                 |            |                             |                             |                             |
| 18   | Warts           | VV+P            | C    | No         | 42+59   |                         |                 |            |                             |                             |                             |
| 19   | Warts           | VV              | V    | No         | 6/11    |                         |                 |            |                             |                             |                             |
| 20   | HGSIL           | C               | C    | No         | 42+35   |                         |                 |            |                             |                             |                             |
| 21   | Warts           | VV              | C    | Yes        | 52      |                         | 52              |            |                             |                             |                             |
| 22   | Warts           | VV              | C    | Yes        | 34      |                         |                 |            |                             |                             |                             |
| 23   | Warts           | VV+VG           | V    | Yes        | 18      |                         |                 |            |                             |                             |                             |
| 24   | Warts           | VV              | V    | No         | 16+73   |                         |                 |            |                             |                             |                             |
| 25   | Warts           | VV+VG           | C    | No         | 68      |                         |                 |            |                             |                             |                             |
| 26   | Warts           | C               | V    | Yes        | 6/11+16 |                         |                 |            |                             |                             |                             |
| 27   | Warts           | C+VV+VG         | V    | No         | 16+58   |                         |                 |            |                             |                             |                             |
| 28   | Warts           | VV              | C    | Yes        | 6/11+33 |                         |                 |            |                             |                             |                             |
| 29   | LGSIL           | C               | V    | No         | 16      |                         |                 |            |                             |                             |                             |
| 30   | LGSIL           | C               | V    | Yes        | 52+42+58+54|                      |                 |            |                             |                             |                             |
| 31   | LGSIL           | C               | C    | No         | 16      |                         |                 |            |                             |                             |                             |
| 32   | Warts           | VV              | C    | No         | 6/11    |                         |                 |            |                             |                             |                             |
Table 3: Clinical and laboratory history of genital HPV infection during pregnancy and delivery and distribution of HPV types in maternal, newborns and children in 1st and 6th and 12th month of life samples. (Continued)

| Case | HPV Type | Delivery Type | Lesion Site | Lesion Type | Presence |
|------|----------|---------------|-------------|-------------|----------|
| 33   | HGSIL    | C             | V           | Yes         | 18       |
| 34   |            | V             | Yes         | 11          | 11       |
| 35   | Warts    | VV            | C           | Yes         | 42       |
| 36   | LGSIL    | V             | C           | Yes         | 16       |
| 37   | HGSIL    | C             | C           | Yes         | 58       |
| 38   | HGSIL    | C             | V           | No          | 6/11+18  |
| 39   | HGSIL    | C             | C           | Yes         | 18+31    |
| 40   | Warts    | VV            | V           | No          | 6/11     |
| 41   | Warts    | VV            | C           | No          | 42       |
| 42   | LGSIL    | C             | C           | Yes         | 42       |
| 43   | LGSIL    | C             | C           | Yes         | 16+18+42 |
| 44   | LGSIL    | C+VV+VG       | C           | Yes         | 18+26    |
| 45   | Warts    | VV            | V           | Yes         | 6/11+58+59 |
| 46   | Warts    | VV+VG         | C           | Yes         | 6        |
| 47   | Warts    | VV            | V           | Yes         | 35       |
| 48   | Warts    | VV            | V           | No          | 70       |
| 49   | Warts    | VV+VG         | V           | No          | 6/45     |
| 50   | LGSIL    | C             | V           | Yes         | -        |
| 51   | Warts    | VV            | C           | No          | -        |
| 52   | HGSIL**  | C             | C           | Yes         | -        |
| 53   | Warts    | VV+VG         | C           | Yes         | -        |
| 54   | HGSIL    | C             | V           | Yes         | -        |
| 55   | LGSIL    | C             | V           | Yes         | -        |
| 56   | HGSIL    | C             | V           | Yes         | -        |
| 57   | HGSIL    | C             | V           | No          | -        |
| 58   | HGSIL    | C             | C           | No          | -        |
| 59   | HGSIL    | C             | C           | Yes         | -        |
| 60   | LGSIL    | C             | V           | No          | -        |
| 61   | HGSIL    | C             | V           | Yes         | -        |
| 62   | LGSIL    | C             | C           | Yes         | -        |
| 63   | HGSIL    | C             | V           | Yes         | -        |

The HPV types were identified by both multiplex PCR and nested multiplex PCR methods. *NC = HPV-DNA positive but could not be classified by type. **Child had anogenital warts (HPV type 6/11) in the 12th month of life.

Delivery type = C – cesarean section; V- vaginal; and V+ F – vaginal with forceps.

HPV lesion site = C – cervical; VG – vaginal; VV – vulva; P- perineal.

HPV lesion type = Warts – genital warts; LGSIL – low-grade squamous intraepithelial lesions; HGSIL – high-grade squamous intraepithelial lesions.
between the maternal genital sample and the samples of the buccal and body scraping, nasopharyngeal aspirate and arterial cord blood of the NB, of 83.3% (n = 5/6), 60% (n = 3/5) and 100% (n = 3/3), respectively. Of the HPV-DNA+ cases, 66.7% and 33.3% were types considered a low and high carcinogenic risk, respectively. The types of HPV-DNA detected were: 6/11 (53.3%); 42, 18, 52 (13.3% each); and 59 (6.7%). One NB (n = 1/11, 9.1%) had HPV-DNA+ for two different types of virus.

Studying the buccal samples of infant, obtained at the end of the first month of life, it was observed that five children (10.2%, n = 5/49) had HPV-DNA+ (Table 3). Three of these children (6.1%, n = 3/49) became HPV-DNA+ during the first month of life, while two were positive since birth. Concordance of the type specific HPV was observed between mother/NB in 100% (n = 3/3) of the new cases. Of the HPV-DNA+ cases, 66.7% and 33.3% were types considered low and high carcinogenic risk, respectively. The types of HPV-DNA detected were: 6/11 (53.3%), 16 and 52 (13.3% each). One NB (20%, n = 1/5) had HPV-DNA+ for two different types of virus. Nine (81.8%, n = 9/11) of the eleven children that were HPV-DNA+ at birth became HPV-DNA negative at the end of the first month of life.

Studying the buccal samples from infant, obtained in the 6th month of life, it was observed that one child (2%, n = 1/49) had become HPV-DNA+ between the 1st and 6th month of life (Table 3). There was agreement of the type specific HPV between the mother/NB (HPV type 6/11). All the children who were HPV-DNA+ (22.4%, n = 11/49) had HPV-DNA+ for two different types of virus. Nine (81.8%, n = 9/11) of the eleven children that were HPV-DNA+ at birth became HPV-DNA negative at the end of the first month of life.

Studying the buccal samples of infant, obtained in the 12th month of life, all the children (30.6%, n = 15/49) who were HPV-DNA+ from birth to the 6th month of life became HPV-DNA negative between the 6th and 12th month of life (Table 3).

One (1.6%, n = 1/63) child had anogenital warts in the 12th month of life. The type of HPV-DNA detected was 6/11. In this case, in epidemiological maternal history, it was observed that the pregnant joined the research for high-grade squamous intraepithelial lesions, with negative result for HPV-DNA. This child was born by cesarian section without early rupture of membranes and by restricted fetal growth. The mother showed normal results in colposcopic and Papanicolaou smear evaluates in the 2nd, 5th, 8th and 12th months postpartum. The buccal samples of the child remained HPV-DNA negative during the 12 months of life.

Analyzing the demographic and behavioral factors (Table 4) a positive and significant correlation was found between the presence of HPV-DNA in the NB or child and maternal history of immunodepression (HIV, p = 0.007).

The statistical analysis did not show any significant association between the presence of HPV-DNA in the NB or child and the other variables studied (Tables 4 and 5).

**HPV detection and typing methods**

Evaluating the HPV-DNA detection and typing methods it was observed that the multiplex PCR methodology identified HPV-DNA in 41 pregnant (83.7%, n = 41/49). In 31 pregnant women (75.6%, n = 31/41) only a single type of HPV-DNA was identified, and in 10 pregnant women (24.4%, n = 10/41) two or more types of HPV-DNA. The nested multiplex PCR method (although used for identification and typing of 9 types of HPV-DNA represented as the most prevalent in the city of Caxias do Sul) identified HPV-DNA in 43 pregnant women (87.8%, n = 43/49). In 28 pregnant women (65.1%, n = 28/43) only one type of HPV-DNA was identified and in 15 pregnant women (34.9%, n = 15/43) two or more types of HPV-DNA. Together the multiplex PCR and nested multiplex PCR methods identified HPV-DNA in 49 pregnant women (100%, n = 49/49). In 19 pregnant women (38.8%, n = 19/49) only one type of HPV-DNA was identified and in 30 pregnant women (61.2%, n = 30/49) two or more types of HPV.

The multiplex PCR method identified HPV-DNA only in two newborns or children (13.3%, n = 2/15), while the nested multiplex PCR method identified it in 13 newborns or children (86.7%, n = 13/15).

**Discussion**

HPV infection is considered a sexually transmitted disease common in sexually active young women, with an estimated prevalence between 20% and 46%[4,22,23]. In pregnant women the prevalence of HPV infection fluctuates around 25%[24,25]. Prior studies suggested that the HPV infection could be transmitted during the perinatal period [26-28]. This is a study between mother and newborn, whose type specific HPV agreement between the pair characterized the vertical transmission of the virus.

The presence of HPV-DNA in the maternal genital area may be considered a risk factor for fetal exposure to the virus. In this study, among the types of HPV identified in the maternal genital samples, 54.9% were considered a high carcinogenic risk. HPV infection has been identified in 1% to 20%[27,29] of babies newly born to pregnant women who do not show any evidence of cervical HPV infection, and in 5% to 72%[30,31] in newborns of women with a diagnosis of the viral infection during pregnancy. Gajewska et al. (2006)[25], detected HPV genital (prevalence of HPV types 6/11 – 18%; HPV type 16 – 13%) in 26% (n = 10/39) of the pregnant women and
observed a high percentage (70%) of HPV transmission from mother to neonate. Rice et al. (2000)[32] identified HPV-DNA type 16 in samples of the oral cavity of children aged 3 to 11 years, and related the results to possible perinatal and interfamilial transmission. On concluding, these authors suggested that in future vaccination programs and studies of the different transmission routes of HPV should be introduced.

Sedlacek et al. (1989)[33] showed the presence of HPV-DNA in nasopharyngeal aspirates of newborns delivered by vaginal route to mothers with HPV-DNA in uterine cervix cells. Authors have described the presence of HPV-DNA in amniotic liquid[13], in cord blood[14], in fetuses with malformations[7] and in specimens from first trimester spontaneous abortions[34]. The presence of HPV-DNA in newborns no implies the presence of viral infections but may demonstrate the mechanism by which the virus can be transmitted during the perinatal period.

In the study discussed here, on analyzing the samples of buccal and body scrapings, nasopharyngeal aspirate and

| Table 4: HPV status of the newborn and children and maternal factors. |
|---------------------------------------------------------------|
| Maternal variable                        | Newborn and children HPV-DNA |
|                                           | Positive (n = 12) | Negative (n = 37) |
| Age (years)                                |               |                     |
| ≤ 19                                       | 6 (50%)        | 17 (45.9%)          |
| ≥ 20 to ≤ 29                               | 3 (25%)        | 12 (32.4%)          |
| ≥ 30 to ≤ 39                               | 3 (25%)        | 6 (16.2%)           |
| ≥ 40 to ≤ 49                               | -              | 2 (5.4%)            |
| Mean for newborn HPV-DNA positive group (25.3 ± 8.1 years) | -              | -                   |
| Mean for newborn HPV-DNA negative group (23.6 ± 8.2 years) | -              | -                   |
| Race                                        |               |                     |
| White                                      | 10 (83.3%)     | 34 (91.9%)          |
| Non-white                                  | 2 (16.7%)      | 3 (8.1%)            |
| Level of education                         |               |                     |
| Illiterate                                 | -              | -                   |
| Elementary (complete or incomplete)        | 7 (58.3%)      | 21 (56.8%)          |
| High school (complete or incomplete)       | 4 (33.3%)      | 16 (43.2%)          |
| College (complete or incomplete)           | 1 (8.4%)       | -                   |
| Smoking                                    |               |                     |
| No                                         | 7 (58.3%)      | 27 (73%)            |
| < 10 cigarettes per day                    | 1 (8.3%)       | 5 (13.5%)           |
| ≥ 10 cigarettes per day                    | 4 (33.3%)      | 5 (13.5%)           |
| Marital status                             |               |                     |
| Married                                    | 1 (8.3%)       | 10 (27%)            |
| Single                                     | 3 (25%)        | 8 (21.6%)           |
| Cohabiting                                 | 7 (58.4%)      | 18 (48.6%)          |
| Divorced, separated                        | 1 (8.3%)       | 1 (2.7%)            |
| Marital stability (years)                  |               |                     |
| ≤ 2                                        | 9 (75%)        | 25 (67.6%)          |
| ≥ 3 to ≤ 5                                 | 2 (16.7%)      | 8 (21.6%)           |
| ≥ 6                                        | 1 (8.3%)       | 4 (10.8%)           |
| Mean for newborn HPV-DNA positive group (2.9 ± 4.6 years) | -              | -                   |
| Mean for newborn HPV-DNA negative group (2.9 ± 4.7 years) | -              | -                   |
| History of Immunodeficiency (HIV)*         |               |                     |
| No                                         | 10 (83.3%)     | 37 (100%)           |
| Yes                                        | 2 (16.7%)      | -                   |

Data are reported as number and percentage (in parentheses) of newborn and children infection positive or negative for human papillomavirus. *P < 0.007 indicates a statistically significant difference between the positive and negative groups by Pearson’s chi-square test (HIV – acquired immunodeficiency syndrome).
Table 5: HPV status of the newborn and children and delivery factors.

| Maternal variable                  | Newborn and children HPV-DNA |
|------------------------------------|-----------------------------|
|                                    | Positive (n = 12) | Negative (n = 37) |
| Type of HPV lesion                 |                   |
| Genital warts                      | 7 (58.3%) | 21 (56.8%) |
| LGSIL<sup>1</sup>                  | 2 (16.7%) | 10 (27%)  |
| HGSIL<sup>2</sup>                  | 3 (25%)  | 6 (16.2%) |
| Site of HPV lesion                 |                   |
| Uterine cervix                     | 5 (41.7%) | 16 (43.2%) |
| Vulva                              | 4 (33.3%) | 12 (32.4%) |
| Vulva + vagina                     | 2 (16.7%) | 5 (13.5%) |
| Vulva + perineal region            | - - | 1 (2.7%) |
| Uterine cervix + vulva + vagina    | 1 (8.3%) | 3 (8.2%) |
| Type of HPV Infection              |                   |
| Single                             | 6 (50%)  | 13 (35.2%) |
| Double                             | 1 (8.3%) | 14 (37.8%) |
| Multiple                           | 5 (41.7%) | 10 (27%)  |
| Type of delivery                   |                   |
| Vaginal                            | 5 (41.7%) | 18 (48.6%) |
| Vaginal + forceps                  | - - | 1 (2.7%) |
| Cesarean section                   | 7 (58.3%) | 18 (48.6%) |
| Mean of the gestational age at delivery in the newborn HPV-DNA positive group (39.3 ± 0.9 weeks) | |
| Mean of the gestational age at delivery in the newborn HPV-DNA negative group (39.3 ± 2.4 weeks) | |
| Gestational age at the time HPV infection was diagnosed (weeks) |                   |
| ≥ 4 to ≤ 12                        | 4 (33.3%) | 15 (40.5%) |
| ≥ 13 to ≤ 28                       | 4 (33.3%) | 8 (21.6%) |
| ≥ 29 to ≤ 42                       | 2 (16.7%) | 6 (16.3%) |
| Prior to pregnancy                 | 2 (16.7%) | 8 (21.6%) |
| Mean in the newborn HPV-DNA positive group (14.6 ± 13.6 weeks) | |
| Mean in the newborn HPV-DNA negative group (13.3 ± 12 weeks) | |
| Time of RUPREME<sup>3</sup> (min)  |                   |
| ≤ 360                              | 12 (100%) | 34 (91.9%) |
| ≥ 361 to ≤ 720                     | - - | 1 (2.7%) |
| ≥ 721                              | - - | 2 (5.4%) |
| Mean of newborn HPV-DNA positive group (39 ± 56 minutes) | - - - |
| Mean of newborn HPV-DNA negative group (103 ± 240 minutes) | - - - |
| Time of labor (min)                |                   |
| ≤ 240                              | 6 (50%)  | 22 (61.1%) |
| ≥ 241 to ≤ 360                     | 3 (25%)  | 9 (25%)  |
| ≥ 361                              | 3 (25%)  | 6 (13.9%) |
| Mean of newborn HPV-DNA positive group (213 ± 225 minutes) | - - - |
| Mean of newborn HPV-DNA negative group (194 ± 196 minutes) | - - - |
| HPV lesion at delivery             |                   |
| Yes                                | 7 (58.3%) | 19 (51.4%) |
| No                                 | 5 (41.7%) | 18 (48.6%) |

Data are reported as number and percentage (in parentheses) of newborn and children infection positive or negative for human papillomavirus. *P < 0.043 indicates a statistically significant difference between the positive and negative groups by Pearson's chi-square test. 1Low-grade squamous intraepithelial lesions. 2High-grade squamous intraepithelial lesions. 3RUPREME = rupture of amniotic membrane.
arterial cord blood obtained in the first minutes of life, it was observed that 11 NB (22.4%, n = 11/49) were positive for HPV-DNA research, 54.9% of which were considered of high carcinogenic risk. Concordance of the type specific HPV was also observed between mother/NB in 16.3% (n = 8/49) of the pairs, characterizing the possibility of transmission of HPV-DNA intrauterine or during the delivery. The different types of HPV identified among the mother/newborn pairs (6.1%, n = 3/49) can be explained by contamination of the sample or of the PCR technique (unlikely, due to the methodologies used to prevent contamination of the PCR methods), or by infection from multiple types of HPV, or by viral subtypes and/or variants.

This study also showed the efficacy of the multiple sample methodology in the newborn, eliminating false negative results for HPV-DNA research. The results obtained corroborate Mazzatenta et al. (1996)[35] who in their study concluded that a simple sample can have a satisfactory result in clinical screening, even if it is not a reliable method to evaluate the risk of vertical transmission of HPV.

The behavior of the presence of HPV-DNA in newborns can be understood by prospective follow up studies and obtaining repeated samples. The present study suggests that the presence of the HPV-DNA in children of mothers HPV-DNA+ in genital sample fluctuates during the first six months of life. Out of the 11 NB who presented HPV-DNA+, only two children continued HPV-DNA+ in samples obtained from the buccal after the first month of life. Three children (6.1%, n = 3/49) became HPV-DNA+ during the first month of life. When children were evaluated in the 6th month of life, all of them became HPV-DNA negative, even if a new case of a HPV-DNA+ appeared for buccal samples. This “regression” of the presence of HPV-DNA in buccal could be explained by the silent neutralization of antibodies that have migrated transplacentally, from the mother to the fetus, and that are functionally active in neonatal circulation, or contamination by maternal infected cells in NB delivered vaginally and that tend to disappear during the first months of life. This diminished number of HPV-DNA+ children could be explained by the results shown by Kawana et al. (2003)[36]. These authors found type 6 anti-HPV antibodies in the maternal blood and in the blood of newborns of infected mothers. The authors suggested that their finding should be better defined and that their study could be considered an important step to understand the prevention of vertical transmission of HPV. Kaye et al. (1996)[37], Cason et al. (1995)[6], Pakarian et al. (1994)[29] Tenti et al. (1999)[38] demonstrated that the HPV-DNA in children examined at three different moments, tends to become negative between birth and the 6th month of life. Puranen et al. (1997)[9] reported the persistence of HPV through-out the first 3 years of life, although the persistence of oral HPV-DNA was not detected in other follow up studies[27,38].

The new cases of children who were HPV-DNA+ in the buccal at the end of the first (n = 3) and sixth (n = 1) month of life, could be explained by the agreement (100%) of the type specific HPV between mother/NB. This agreement of HPV-DNA suggests that these children may have been exposed to HPV-DNA: during the intrauterine period or during the delivery and that the HPV-DNA was only identified after birth[39]; or during the post-birth period, when caring for the child (interfamilial transmission – mother/child)[40].

One (n = 1/63, 1.6%) child had anogenital warts (HPV-DNA type 6/11) in the 12th month of life. The incidence of anogenital warts in children has increased dramatically since 1990 [41-43]. Before 1990, only 136 cases of anogenital warts had been reported in children, yet between 1990 and 1994, at least 326 additional cases were described [42,43]. The increase in incidence of anogenital warts in children is thought to parallel the increase in incidence of anogenital warts in the adult population[43]. Adams (2001)[44] classification scale for evaluation medical findings of suspected sexual abuse lists anogenital warts/condyloma in a child younger than 2 years of age as a nonspecific finding for sexual abuse-perinatal transmission must be considered. Vertical transmission can occur through the bloodstream prior to birth, or at the time of birth, as the infant passes through the infected birth canal. Delivery via cesarean section does not eliminate the possibility of vertical transmission of HPV; there are reports of congenital condyloma after cesarean section without premature rupture of membranes[43]. HPV can be transmitted no sexually from direct contact with caretaker contaminated with genital HPV or common warts [41,43]. For example, caretakers with genital warts who touch or scratch their genitals and then without washing their hands change a baby’s diaper or assist a child with toiletting/bathing may transmit the virus to the child’s genitals. A caretaker with common warts of the hands could transmit HPV in the same manner. HPV transmission via contact with contaminated objects or surfaces is possible [43]. Sexual abuse must never be eliminated when considering possible modes of transmission for anogenital HPV in younger children[42].

In three cases no concordance of the type specific HPV between mother/NB were observed. The different types of HPV-DNA identified among the mother/NB pairs can be explained by infection from multiple types of HPV, or by viral subtypes and/or variants.

The positive and significant correlation between presence HPV-DNA+ in the newborn or child and the maternal var-
ibles "history of immunodepression" (HIV, p = 0.007) may be related to the special characteristics of the pregnancy, especially to the changes in the hormonal and immunological balance prevailing during this period, which could favor vertical transmission of the virus. In adults, the risk factors for HPV-DNA transmission have been well established. The chances of perinatal transmission and the differences in the known rates of HPV-DNA transmission, are probably more closely related to the viral load of the infected cells than to the risk factors established for HPV infection[38].

Although the nested multiplex PCR methodology is used to identify only 9 types of HPV represented as the most prevalent in the city of Caxias do Sul, it had an excellent performance to identify maternal HPV-DNA, and also considerably increased the total number of pregnant women with infections caused by multiple viruses. In the samples of newborns, the nested multiplex PCR showed its great sensitivity and specificity to identify HPV. The use of that method was also essential to evaluate the agreement of type specific HPV-DNA between the maternal/newborn samples, thus defining the perinatal transmission rates.

The perinatal transmission of HPV-DNA was suggested when concordance of the type specific HPV was observed between mother/NB and mother/child: eight newborns, three children at the end first month of life and a child in the 6th month of life. In conclusion, perinatal transmission of HPV-DNA was suggested in 24.5% (n = 12/49) of the newborns of mothers with genital warts or intraepithelial lesions of the uterine cervix. Thus, a different management can be adopted for each of the different stages (pre-gestational, gestation, delivery, and the first months post partum), both from the diagnostic and therapeutic perspective. Clinical observation of the mother and the newborn must be maintained, and preventive educational measures established for forms of HPV-DNA transmission, besides effective strategies for specific immunization.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
RLR participated in the design of the study, sampling methods and performed the statistical analysis. RLR made substantial contributions to conception and design, acquisition of data and analysis and interpretation of data. EPS has been involved in drafting the manuscript or revising it critically for important intellectual content.

EPS and JM conceived of the study, and participated in its design and coordination. RLR, EPS, JM, KPL and EZ participated in the sequence alignment and drafted the manuscript. JM, KPL and EZ carried out the molecular studies.

RLR, EPS, JM, KPL and EZ have given final approval of the version to be published.

References
1. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S, Stanton CK, Manos MM: Epidemiologic Evidence Showing That Human Papillomavirus Infection Causes Most Cervical Intraepithelial Neoplasia. J Natl Cancer Inst 1993, 85:958-964.
2. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zambak ML, Daniel RW, Vignone M, Symer DE, Shah KV, Sidransky D: Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck Cancers. J Natl Cancer Inst 2000, 92:709-720.
3. zur Hausen H: Papillomaviruses in human cancers. Proc Assoc Am Physicians 1999, 111:581-587.
4. Munoz N: Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000, 19:1-5.
5. Rice PS, Cason J, Best JM, Banatvala JE: High risk genit al papillomavirus infections are spread vertic ally. Rev Med Virol 1999, 9:15-21.
6. Cason J, Kaye JN, Jewers RJ, Kambo PK, Bible JM, Kell B, Shergill B, Pakarian F, Raju KS, Best JM: Perinatal infection and persistence of human papillomavirus types 16 and 18 in infants. J Med Virol 1995, 47:209-218.
7. Eppel W, Worda C, Frigo P, Ulm M, Kucera E, Czerwenka K: Human papillomavirus in the cervix and placenta. Obstet Gynecol 2000, 96:337-341.
8. Minkoff H, Chervenak FA: Elective primary cesarean delivery. N Engl J Med 2003, 348:946-950.
9. Puranen MH, Ylisoskoski MH, Saarikoski SV, Syrjanen KJ, Syrjanen SM: Exposure of an infant to cervical human papillomavirus infection of the mother is common. Ann J Obstet Gynecol 1997, 176:1039-1045.
10. Xue S, Liu L, Lu S, Ren S: Clinical observation on vertical transmission of human papillomavirus. Chin Med Sci J 1998, 13:29-31.
11. Favre M, Majewski S, De Jesus N, Malejczyk M, Orth G, Jablonska S: A possible vertical transmission of human papillomavirus genotypes associated with epidermodysplasia verruciformis. J Invest Dermatol 1998, 111:333-336.
12. Wang X, Zhu Q, Rao H: Maternal-fetal transmission of human papillomavirus. Chin Med J (Engl) 1998, 111:726-727.
13. Armbruster-Moraes E, Ioshimoto L, Leao E, Zugaib M: Molecular epidemiology of genital human papillomaviruses in Brazil. Braz J Med Biol Res 2000, 33:152-158.
14. Tseng CJ, Lin CY, Wang RL, Chen LJ, Chang YL, Hsieh TT, Pao CC: Possible placental transmission of human papillomaviruses. J Obstet Gynecol 1996, 16:35-40.
15. Silverberg MJ, Thorson P, Lindeberg H, Grant LA, Shah KV: Condyloma in Pregnancy Is Strongly Predictive of Juvenile-Onset Recurrent Respiratory Papillomatosis. Obstet Gynecol 2003, 101:645-652.
16. Obalek S, Jablonska S, Favre M, Walczak L, Orth G: Condylomata acuminata in children: frequent association with human papillomaviruses responsible for cutaneous warts. J Am Acad Dermatol 1990, 23:205-213.
17. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ: Improved Amplification of Genital Human Papillomaviruses. J Clin Microbiol 2000, 38:357-361.
18. Bernard H, Chan S, Manos M, Ong C, Villa L, Delius H, Peyton C, Bauer H, Wheeler C: Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994, 170:1077-1085.
20. Soltra K, Diemer D, Dethlefs A, Hack Y, Stüber A, Vollmer N, Menton S, Plentien M, Dietz K, Wallwiener D, Kodand R, Bultmann B: Detection and Typing of Human Papillomavirus by E6 Nested Multiplex PCR. J Clin Microbiol 2004, 42:3176-3184.

21. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PF, Meijer CJLM, the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med 2003, 348:518-527.

22. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE: Prevalence of HPV Infection Among Females in the United States. JAMA 2007, 297:813-819.

23. Avvinen E, Zillerius R, Malm C, Koksulainen T, Fingeroos R, Pasovonen J: Repeated human papillomavirus DNA findings among female university students. Int J STD AIDS 2007, 18:839-841.

24. Hernandez-Giron C, Smith JS, Lomnicz A, Arreola Chaidez E, Lazcano-Ponce E, Hernandez-Avila M, Salmeron J: [The prevalence of high-risk HPV infection in pregnant women from Morelos, Mexico]. Salud Publica Mex 2005, 47:423-429.

25. Gajewska M, Wielgos M, Kaminiski P, Marianowski P, Maleczyk M, Majewski S, Marianowski L: The occurrence of genital types of human papillomavirus in normal pregnancy and in pregnant renal transplant recipients. Neuro Endocrinol Lett 2006, 27:529-534.

26. Smith EM, Ritchie JM, Yankowitz J, Swarnavel S, Wang D, Haugen TH, Turek LP. Human papillomavirus prevalence and types in newborns and parents: concordance and modes of transmission. Sex Transm Dis 2004, 31:57-62.

27. Watts DH, Koutsy LA, Holmes KK, Goldman D, Kuyers J, Kiviat NB, Galloway DA: Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. Am J Obstet Gynecol 1998, 178:365-373.

28. Puranen M, Yliaskoski M, Saarikoski S, Syrjanen K, Syrjanen S: Vertical transmission of human papillomavirus from infected mothers to their newborn babies and persistence of the virus in childhood. Am J Obstet Gynecol 1996, 174:694-699.

29. Pakarian F, Kaye J, Cason J, Kell B, Jewers R, Derias NW, Raju KS, Best JM. Cancer associated human papillomaviruses: perinatal transmission and persistence. Br J Obstet Gynaecol 1994, 101:514-517.

30. Fredericks BD, Balkin A, Daniel HW, Schonrock J, Ward B, Frazer IH: TP53 mutation of human papillomavirus-infected skin in newborns and parents: concordance and modes of transmission. Sex Transm Dis 2004, 31:57-62.

31. Smid EM, Johnson SR, Jiang D, Zaleski S, Lynch CF, Brundage S, Anderson RD, Turek LP: The association between pregnancy and human papilloma virus prevalence. Cancer Detect Prev 1997, 21:397-402.

32. Rice PS, Mant C, Cason J, Bible JM, Muir P, Kell B, Best JM: High prevalence of human papillomavirus type 16 infection among children. J Med Virol 2000, 61:70-75.

33. Seldlacek T, Lindheim S, Eder C, Hasty L, Woodland M, Ludomirsky A, Rando R: Mechanism for human papillomavirus transmission at birth. Am J Obstet Gynecol 1998, 178:451-458.

34. Hermonat PL, Han L, Wandel P, Quirk JG, Stern S, Lowery CL, Rechtin TM: Human papillomavirus is more prevalent in first trimester spontaneously aborted products of conception compared to elective specimens. Virus Genes 1997, 14:13-17.

35. Mazzatenta C, Finimiani M, Rubegni P, Andreassi L, Buffo P, Messina C: Vertical transmission of human papillomavirus in cytologically normal women. Genet_serv Med 1996, 72:445-446.

36. Kawana K, Yasugi T, Yoshikawa H, Kawana Y, Matsumoto K, Nakagawa S, Onda T, Iikuchi A, Fujii T, Kanda T, Taketani Y: Evidence for the presence of neutralizing antibodies against human papillomavirus type 6 in infants born to mothers with condyloma acuminate. Am J Perinatol 2003, 20:11-16.

37. Kaye JM, Starkey WG, Kell B, Biswas C, Raju KS, Best JM, Cason J: Human papillomavirus type 16 in infants: use of DNA sequence analyses to determine the source of infection. J Gen Virol 1996, 77(Pt 6):1139-1143.

38. Tenti P, Zappatore R, Migliora P, Spinillo A, Belloni C, Carnevali L: Perinatal transmission of human papillomavirus from gravidas with latent infections. Obstet Gynecol 1999, 93:475-479.

39. Leptak C, Ramon y Cajal S, Kulke R, Horwitz BH, Riese DJ 2nd, Dotto GP, DiMaio D: Tumorigenic transformation of murine keratinocytes by the ES genes of bovine papillomavirus type 1 and human papillomavirus type 16. J Virol 1991, 65:7078-7083.

40. Cripe TP, Haugen TH, Turk JP, Tabatabai F, Schmid PG 3rd, Durst M, Gissmann L, Roman A, Turek LP: Transcriptional regulation of the human papillomavirus-16 E6-E7 promoter by a keratinocyte-dependent enhancer, and by viral E2 trans-activator and repressor gene products: implications for cervical carcinogenesis. Embo J 1987, 6:3745-3753.

41. Cohen BA: Warts and children: Can they be separated? JAAPA. 1997, 11(12):63-68.

42. Siegfried E, Rasnick-Conley J, Cook S, Leonardi C, Monteleone J: Human Papillomavirus Screening in Pediatric Victims of Sexual Abuse. Pediatrics 1998, 101:43-47.

43. Syrjanen S, Puranen M: Human papillomavirus infections in children: the potential role of maternal transmission. Crit Rev Oral Biol Med 2000, 11:259-274.

44. Adams JA: Evolution of a Classification Scale: Medical Evaluation of Suspected Child Sexual Abuse. Child Maltreat 2001, 6:31-36.

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp